Antiphospholipid syndrome; its implication in cardiovascular diseases: A review

Journal of Cardiothoracic Surgery

Volumn 5, Issue 1, 2010, Pages

  Koniari, Ioanna ^a   Siminelakis, Stavros N ^b   Baikoussis, Nikolaos G ^a   Papadopoulos, Georgios ^b   Goudevenos, John ^b   Apostolakis, Efstratios ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOLIPID ANTIBODY;

ACUTE CORONARY SYNDROME; ANTIPHOSPHOLIPID SYNDROME; CARDIOVASCULAR DISEASE; FEMALE; HEART SURGERY; HUMAN; PATHOPHYSIOLOGY; PEROPERATIVE COMPLICATION; PHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATION; RESTENOSIS; REVIEW; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, BALLOON, CORONARY; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; CARDIAC SURGICAL PROCEDURES; CARDIOVASCULAR DISEASES; CORONARY RESTENOSIS; FEMALE; HUMANS; INTRAOPERATIVE COMPLICATIONS; PREGNANCY; PREGNANCY COMPLICATIONS; THROMBOSIS;

EID: 78049330155     PISSN: None     EISSN: 17498090     Source Type: Journal    
DOI: 10.1186/1749-8090-5-101     Document Type: Article

References (99)

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RHWM, DeGroot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306. 10.1111/j.1538-7836.2006.01753.x, 16420554.
2. Gorki H, Malinovski V, Stanbridge RDL. The antiphospholipid syndrome and heart valve surgery. Eur J CardioThorac Surg 2008, 33:168-18. 10.1016/j.ejcts.2007.11.004, 18082413.
3. Tripodi A, Chantarangkul V, Clerici M, Negri B, Galli M, Mannucci PM. Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins. Br J Haematol 2001, 115:672-8. 10.1046/j.1365-2141.2001.03178.x, 11736953.
4. Asherson RA, Piette JC. The catastrophic antiphospholipid syndrome: acute multiorgan failure associated with antiphospholipid antibodies: a review of 31 patients. Lupus 1996, 5:414-7.
5. Hedge VAP, Vivas Y, Shah H, Haybron D, Srinivasan V, Dua A, Gradman A. Cardiovascular surgical outcomes in patients with the antiphospholipid syndrome- a case series. Heart, Lung and Circulation 2007, 16:423-427.
6. Gurlek A, Ozdol C, Pamir G, et al. Association Between Anticardiolipin Antibodies and Recurrent Cardiac Events in Patients With Acute Coronary Syndrome. Int Heart J 2005, 46:631-638. 10.1536/ihj.46.631, 16157954.
7. Turiel M, Muzzupappa S, Gottardi B. Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography. Lupus 2000, 9:406-12. 10.1191/096120300678828532, 10981643.
8. Weiss S, Nyzio JB, Cines D, Detre J, Milas BL, Narula N, Floyd TF. Antiphospholipid syndrome Intraoperative and postoperative anticoagulation in cardiac surgery. J Cardiothorac Vasc Anesth 2008, 22:735-9. 10.1053/j.jvca.2008.01.021, 18922433.
9. Greaves M, Cohen H, MacHin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000, 109:704-15. 10.1046/j.1365-2141.2000.02069.x, 10929019.
10. Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003, 102:2717-23. 10.1182/blood-2002-11-3334, 12816875.
11. Oosting JD, Derksen RH, Bobbink IW, Hackeng TM, Bouma BN, deGroot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?. Blood 1993, 81:2618-25.
12. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, Barbui T, Zwaal RF, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990, 335:1544-7. 10.1016/0140-6736(90)91374-J, 1972485.
13. Pierangeli SS, Espinola RG, Liu X, Harris EN. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res 2001, 88:245-50.
14. Roubey RA. Tissue factor pathway and the antiphospholipid syndrome. Autoimmunol 2000, 15:217-20.
15. Lutters BCH, Derksen RHWM, Tekelenburg WL, Lenting PJ, Arnout J, deGroot PG. Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2'. J Biol Chem 2003, 278:33831-8. 10.1074/jbc.M212655200, 12807892.
16. Ma K, Simantov R, Zhang JC, Silverstein R, Hajjar KA, McCrae KR. High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem 2000, 275:15541-8. 10.1074/jbc.275.20.15541, 10809787.
17. Mackworth-Young CG. Antiphospholipid syndrome: Multiple mechanisms. Clin Exp Immunol 2004, 136:393-401. 10.1111/j.1365-2249.2004.02497.x, 1809064, 15147339.
18. Dornan RI. Acute postoperative biventricular failure associated with antiphospholipid antibody syndrome. Br J Anaesth 2004, 92:748-54. 10.1093/bja/aeh116, 15003982.
19. Love PE, Santaro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med 1990, 112:682-98.
20. Mackworth-Young C. Antiphospholipin antibodies: more than just a disease marker?. Immunol Today 1990, 11:60-5. 10.1016/0167-5699(90)90020-A, 2185781.
21. Rand JH, Wu XX, Andree HAM, et al. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a "lupus procoagulant" phenomenon. Blood 1998, 92:1652-60.
22. East C, Clements F, Mathew J, et al. Antiphospholipid Syndrome and Cardiac Surgery: Management of anticoagulation in two Patients. Anesth Analg 2000, 90:1098-101. 10.1097/00000539-200005000-00017, 10781459.
23. Meroni PL, Borghi MO, Raschi E, et al. Inflammatory response and the endothelium. Thromb Res 2004, 114:329-334. 10.1016/j.thromres.2004.06.045, 15507262.
24. Cervera R. Recent advances in antiphospholipid antibodyrelated valvulopathies. J Autoimmun 2000, 15:123-5. 10.1006/jaut.2000.0405, 10968897.
25. Erdogan D, Goren MT, Diz-Kucukkaya R, et al. Assessment of cardiac structure and left atrial appendage functions in primary antiphospholipid syndrome: A transesophageal echocardiographic study. Stroke 2005, 36:592-596. 10.1161/01.STR.0000154858.27353.df, 15677581.
26. Sakaguchi G, Minami K, Nakayama S. Aortic valve replacement after previous coronary artery bypass grafting in a patient with antiphospholipid syndrome. Jpn J Thorac Cardiovasc Surg 1998, 46:257-9.
27. Schumacher M, Eber B, Dusleag J, Fruhwald FM, Zweiker R, Pokan R, Klein W. Thrombosis of a prosthetic mitral valve in the anticardiolipin syndrome. Dtsch Med Wochenschr 1995, 120:795-8. 10.1055/s-2008-1055410, 7781511.
28. Hogan WJ, McBane RD, Santrach PJ, Plumhoff EA, Oliver WC, Schaff HV, Rodeheffer RJ, Edwards WD, Duffy J, Nichols WL. Antiphospholipid syndrome and perioperative hemostatic management of cardiac valvular surgery. Mayo Clin Proc 2000, 75:971-6. 10.4065/75.9.971, 10994834.
29. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002, 346:752-63. 10.1056/NEJMra002974, 11882732.
30. Nakayama M, Kumon K, Yahagi N, et al. Antiphospholipid antibody syndrome in a case with redo coronary artery bypass grafting under cardiopulmonary bypass. Surg Today 1998, 28:423-426. 10.1007/s005950050155, 9590711.
31. Ciocca RG, Choi J, Graham AM. Antiphospholipid antibodies lead to increased risk in cardiovascular surgery. Am J Surg 1995, 170:198-200. 10.1016/S0002-9610(99)80285-2, 7631930.
32. Jorgensen P, Hansen PR. Antiphospholipid antibodies and ischaemic heart disease. J Intern Med 1993, 233:291-293. 10.1111/j.1365-2796.1993.tb00990.x, 8450299.
33. Tektonidou MG, Ionnidis JPA, Boki KA, Vlachoyiannopoulos PG, Moutsopoulos HM. Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome. Q J Med 2000, 93:523-30.
34. Harris EN, Hughes GR, Gharav AE. Antiphospholipid antibodies: an elderly statesman dons new garments. J Rheumatol 1987, 14(Suppl 13):208-13.
35. Shapiro SS, Thiagarajan P. Lupus anticoagulants. Prog Hemost Thromb 1982, 6:263-85.
36. Erkan D, Lockshin. Non-criteria manifestations of antiphospholipid syndrome. Lupus 2010, 19(4):424-7. 10.1177/0961203309360545, 20353981.
37. Asherson RA, Cervera R, Piette JC, Shoenfeld Y, Espinosa G, Petri MA, Lim E, Lau TC, Gurjal A, Jedryka-Góral A, Chwalinska-Sadowska H, Dibner RJ, Rojas-Rodríguez J, García-Carrasco M, Grandone JT, Parke AL, Barbosa P, Vasconcelos C, Ramos-Casals M, Font J, Ingelmo M. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Med Baltim 2001, 80:355-77.
38. Greaves M, Cohen H, MacHin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000, 109:704-15. 10.1046/j.1365-2141.2000.02069.x, 10929019.
39. Triplett DA. Coagulation assays for the lupus anticoagulant: review and critique of current methodology. Stroke 1992, 23(Suppl I):11-4.
40. Eby C. Standardization of APTTreagents for heparin therapy monitoring: urgent or fading priority?. Clin Chem 1997, 43:1105-7.
41. Arvieux J, Darnige L, Hachulla E, Roussel B, Bensa JC, Coulomb MG. Species specificity of anti-beta 2 glycoprotein I autoantibodies and its relevance to anticardiolipin antibody quantitation. Thromb Haemost 1996, 75:725-30.
42. Bertolaccini ML, Atsumi T, Koike T, Hughes GRV, Khamashta MA. Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb Haemost 2005, 93:289-97.
43. Hughes GR. The antiphospholipid syndrome: ten years on. Lancet 1993, 342:341-4. 10.1016/0140-6736(93)91477-4, 8101587.
44. Eber B, Kronberger-Schaffer E, Brusee H, et al. Anticardiolipin antibodies are no marker for survived myocardial infarction. Klin Wochenschr 1990, 68:594-6. 10.1007/BF01660956, 2376955.
45. Ludia C, Domenico P, Monia C, et al. Antiphospholipid antibodies: a new risk factor for restenosis after percutaneous transluminal coronary angioplasty?. Autoimmunity 1998, 27:141-8. 10.3109/08916939809003861, 9609131.
46. Chiarugi L, Prisco D, Antonucci E, et al. Lipoprotein (a) and anticardiolipin antibodies are risk factors for clinically relevant restosis after elective balloon precutaneus transluminal coronary angioplasty. Atherosclerosis 2001, 154:129-35. 10.1016/S0021-9150(00)00439-1, 11137091.
47. Sharma S, Malhotra A, Sharma YP, Pandhi P, Malhotra S, Nageswari KS, Shafiq N, Venkateshan SP, Kaur R. Association of anticardiolipin antibodies levels with instent restenosis in patients with coronary artery disease. Indian J Physiol Pharmacol 2008, 52(3):288-92.
48. Bili A, Moss AJ, Francis CW, Zareba W, Watelet LF, Sanz I. Anticardiolipin antibodies and recurrent coronary events: a prospective study of 1150 patients. Thrombogenic Factors, and Recurrent Coronary Events Invertigators. Circulation 2000, 102:1258-63.
49. Zuckerman E, Toubi E, Shiran A, et al. Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythematosus patients: a controlled prospective study. Am J Med 1996, 104:381-6.
50. Hamsten Ai Norberg R, Bjorkholm M, de Faire U, Holm G. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet 1986, 1:113-6. 10.1016/S0140-6736(86)92258-0, 2867345.
51. Sletnes KE, Smith P, Abdelnoor N, Arnesen H, Wisloff F. Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-hemorrhagic stroke. Lancet 1992, 339:451-3. 10.1016/0140-6736(92)91057-F, 1346819.
52. Cortellaro M, Boschetti C, Cardillo M, Barbui T. Antiphospholipid antibodies in patients with previous myocardial infaction. Lancet 1992, 339:929-30. 10.1016/0140-6736(92)90966-7, 1348318.
53. Phadke KV, Phillips RA, Clarke DT, Jones M, Naish P, Carson P. Anticardiolipin antibodies in ischemic heart disease: marker or myth?. Br Heart J 1993, 69:391-4. 10.1136/hrt.69.5.391, 1025099, 8518060.
54. Warkentin TE, Aird WC, Rand JH. Platelet-Endothelial Interactions: Sepsis, HIT, and Antiphospholipid Syndrome. Hematology 2003, 1:497-519.
55. Berkun Y, Elami A, Meir K, et al. Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery. J Thorac Cardiovasc Surg 2004, 127:414-420. 10.1016/j.jtcvs.2003.07.016, 14762349.
56. Leissner K, Ketchedjian A, Crowley R, et al. Deep hypothermic circulatory arrest and Bivalirudin use in a patient with heparin-induced thrombocytopenia and antiphospholipid syndrome. J Card Surg 2007, 22:78-82. 10.1111/j.1540-8191.2007.00351.x, 17239224.
57. Green JA, Spiess BD. Current status of antifibrinolytics in cardiopulmonary bypass and elective deep hypothermic circulatory arrest. Anesthesiol Clin North America 2003, 21:527-551. 10.1016/S0889-8537(03)00042-7, 14562564.
58. Despotis GJ, Joist JH, Hogue CW, et al. The impact of heparin concentration and cativated clotting time monitoring on blood conservation. J Thorac Cardiovasc Surg 1995, 110:46-54. 10.1016/S0022-5223(05)80008-X, 7609568.
59. Hogan WJ, McBane RD, Santrach PJ, et al. Antiphospholipid syndrome and perioperative haemostatic management of cardiac valvular surgery. Mayo Clin Proc 2000, 75:971-6. 10.4065/75.9.971, 10994834.
60. East CJ, Clements F, Mathew J, Slaughter TF. Antiphospholipid syndrome and cardiac surgery: management of anticoagulation in two patients. Anesth Analg 2000, 90:1098-101. 10.1097/00000539-200005000-00017, 10781459.
61. Shiekh F, Lechowicz A, Setlur R, et al. Recognition and management of patients with antiphospholipid antibody syndrome undergoing cardiac surgery. J Cardiothor Vasc Anesth 1997, 11:764-6.
62. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995, 332:993-7. 10.1056/NEJM199504133321504, 7885428.
63. Della Valle P, Crippa L, Garlando A-M, et al. Interference of lupus anticoagulants in prothrombin time assays: implications for selection of adequate methods to optimize the management of thrombosis in antiphospholipid-antibody syndrome. Haematologica 1999, 84:1065-1074.
64. Rivier G, Herranz MT, Khamashta MA, Hughes GRV. hrombosis and antiphospholipid syndrome: a preliminary assessment of three antithrombotic treatments. Lupus 1994, 3:85-90. 10.1177/096120339400300205, 7920619.
65. Asherson RA, Cervera R, Merrill JT, Erkan D. Antiphospholipid antibodies and the antiphospholipid syndrome: clinical significance and treatment. Semin Thromb Hemost 2008, 34(3):256-66. 10.1055/s-0028-1082269, 18720305.
66. Lockshin MD. Answers to the antiphospholipid-antibody syndrome?. N Engl J Med 1995, 332:1025-7. 10.1056/NEJM199504133321510, 7885409.
67. Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies. A five-year prospective study from the Italian registry. Am J Med 1996, 100:530-6. 10.1016/S0002-9343(96)00060-5, 8644765.
68. Ginsberg JS, Wells PS, Brill-Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995, 86:3685-91.
69. Schulman S, Svenungsson E, Granqvist S, . The Duration of Anticoagulation Study Group Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998, 104:332-8. 10.1016/S0002-9343(98)00060-6, 9576405, The Duration of Anticoagulation Study Group.
70. Haemostasis and Thrombosis Task Force. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000, 109:704-15. 10.1046/j.1365-2141.2000.02069.x, 10929019.
71. Tripodi A, Chantarangkul V, Clerici M, Negri B, Galli M, Mannucci PM. Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins. Br J Haematol 2001, 115:672-8. 10.1046/j.1365-2141.2001.03178.x, 11736953.
72. Gordon G, Rastegar H, Schumann R, et al. Successful use of bivalirudin for cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. J Cardiothorac Vasc Anesth 2003, 17:632-635. 10.1016/S1053-0770(03)00210-6, 14579220.
73. Harpaz D, Glikson M, Side Y, Hod H. Successful thrombolytic therapy for acute myocardial infarction in a patient with the antiphospholipid antibody syndrome. Am Heart J 1991, 122:1492-4. 10.1016/0002-8703(91)90604-G, 1951025.
74. Merry AF. Bivalirudin, blood loss, and graft patency in coronary artery bypass surgery. Semin Thromb Hemost 2004, 30:337-346. 10.1055/s-2004-831046, 15282656.
75. Koster A, Yeter R, Buz S, et al. Assessment of hemostatic activation during cardiopulmonary bypass for coronary artery bypass grafting with bivalirudin: Results of a pilot study. J Thorac Cardiovasc Surg 2005, 129:1391-1394. 10.1016/j.jtcvs.2004.09.016, 15942583.
76. Clayton SB, Acsell JR, Crumbley AJ, et al. cardiopulmonary bypass with bivalirudin in type II heparin- nduced thrombocytopenia. Ann Thorac Surg 2004, 78:2167-2169. 10.1016/S0003-4975(03)01471-1, 15561064.
77. Merry AF, Raudkivi PJ, Middleton NG, et al. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Ann Thorac Surg 2004, 77:925-931. 10.1016/j.athoracsur.2003.09.061, 14992900.
78. Mann MJ, Tseng E, Ratcliffe M, et al. Use of bivalirudin, a direct thrombin inhibitor, and its reversal with modified ultrafiltration during heart transplantation in a patient with heparin-induced thrombocytopenia. J Heart Lung Transplant 2005, 24:222-225. 10.1016/j.healun.2003.11.401, 15701441.
79. Greinacher A. The use of direct thrombin inhibitors in cardiovascular surgery in patients with heparin-induced thrombocytopenia. Semin Thromb Hemost 2004, 30:315-327. 10.1055/s-2004-831044, 15282654.
80. Weitz JI, Bates SM. New anticoagulants. J Thromb Haemost 2005, 3:1843-1853. 10.1111/j.1538-7836.2005.01374.x, 16102051.
81. Koster A, Spiess B, Chew DP, et al. Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting. Am J Cardiol 2004, 93:356-359. 10.1016/j.amjcard.2003.10.021, 14759391.
82. Dyke CM, Koster A, Veale JJ, et al. Preemptive use of Bivalirudin for urgent on-pump coronary artery bypass grafting in patients with potential heparin-induced thrombocytopenia. Ann Thorac Surg 2005, 80:299-303. 10.1016/j.athoracsur.2004.08.037, 15975385.
83. Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine 2001, 80:355-77. 10.1097/00005792-200111000-00002, 11704713.
84. Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome: Clinical and laboratory features of 50 patients. Medicine 1998, 77:195-207. 10.1097/00005792-199805000-00005, 9653431.
85. Asherson R, Cervera R. Antiphospholipid antibodies and the heart. Lessons and pitfalls for the cardiologist. Circulation 1991, 84:920-3.
86. Menon G, Allt-Graham J. Anaesthetic implications of the anticardiolipin antibody syndrome. Br J Anaesth 1993, 70:587-90. 10.1093/bja/70.5.587, 8318336.
87. Brown JH, Doherty CC, Allen DC, Morton P. Fatal cardiac failure due to myocardial microthrombi in systemic lupus erythematosus. BMJ 1988, 296:1505. 10.1136/bmj.296.6635.1505, 2546021, 3134088.
88. McCarthy RE, Boehmer JP, Hruban RH, et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 2000, 342:690-5. 10.1056/NEJM200003093421003, 10706898.
89. Murphy JJ, Leach IA. Findings at necropsy in the heart of a patient with anticardiolipin syndrome. Br Heart J 1989, 62:61-4. 10.1136/hrt.62.1.61, 1216732, 2757875.
90. Nagappan R, Lodge RS. Acute autoimmune cardiomyopathy in primary antiphospholipid antibody syndrome. Anaesth Intens Care 2002, 30:226-9.
91. Sherer Y, Snoenfeld Y. Antiphospholipid syndrome: insights from animal models. Curr Opin Hematol 2000, 7:321-4. 10.1097/00062752-200009000-00011, 10961584.
92. Vega Ostertag M, Liu X, Henderson V, Pierangeli SS. A peptide that mimics the Vth region of beta-2-glycoprotein I reverses antiphospholipid-mediated thrombosis in mice. Lupus 2006, 15:358-65. 10.1191/0961203306lu2315oa, 16830882.
93. Morton KE, Gavaghan TP, Krilis SA, et al. Coronary artery bypass graft failure -An autoimmune phenomenon?. Lancet 1986, (ii):1353-6. 10.1016/S0140-6736(86)92004-0, 2878224.
94. Myers G, Hirsch G. Double valve replacement in a patient with anticardiolipin antibody syndrome. Perfusion 1999, 14:397-401.
95. Asherson R, Weinberger A, Kinsley R. Radial artery occlusion in primary antiphospholipid syndrome after aortic valve replacement. S Afr Med J 1995, 85:1042.
96. Sheikh F, Lechowicz A, Selut R, Rauch A, Dunn H. Recognition and management of patients with antiphospholipid antibody syndrome undergoing cardiac surgery. J Cardiothorac Vasc Anesth 1997, 11:764-6. 10.1016/S1053-0770(97)90173-7, 9327321.
97. Ando M, Takamoto S, Okita Y, et al. Operation for chronic pulmonary thromboembolism accompanied by thrombophilia in 8 patients. Ann Thorac Surg 1998, 66:1919-24. 10.1016/S0003-4975(98)00910-2, 9930469.
98. Ducart AR, Collard EL, Osselaer JC, Broka SM, Eucher PM, Joucken KL. Management of anticoagulation during cardiopulmonary bypass in a patient with a circulating lupus anticoagulant. J Cardiothorac Vasc Anesth 1997, 11:878-9. 10.1016/S1053-0770(97)90125-7, 9412889.
99. Colli A, Mestres CA, Espinosa G, Plasín MA, Pomar JL, Font J, Cervera R. Heart valve surgery in patients with the antiphospholipid syndrome: analysis of a series of nine cases. Eur J Cardiothorac Surg 2010, 37(1):154-8. 10.1016/j.ejcts.2009.06.046, 19699100.